MN1 overexpression is an important step in the development of inv(16) AML

Leukemia

Volumn 21, Issue 8, 2007, Pages 1679-1690

  Carella, C ^a   Bonten, J ^a   Sirma, S ^a   Kranenburg, T A ^a   Terranova, S ^a   Klein Geltink, R ^a   Shurtleff, S ^a   Downing, J R ^a   Zwarthoff, E C ^b   Liu, P P ^c   Grosveld, G C ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^c NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORE BINDING FACTOR BETA; HYBRID PROTEIN; MENINGIOMA 1 PROTEIN; MYOSIN HEAVY CHAIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR MN1; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CULTURE; BONE MARROW TRANSPLANTATION; CHROMOSOME 16; CHROMOSOME ABERRATION; CHROMOSOME INVERSION; CONTROLLED STUDY; ECOTROPIC VIRUS; FEMALE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; KARYOTYPE; LEUKEMOGENESIS; MALE; MICROARRAY ANALYSIS; MOUSE; MYELOPROLIFERATIVE DISORDER; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN FUNCTION; VIRUS DNA CELL DNA INTERACTION;

EID: 34447642168     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404778     Document Type: Article

References (46)

1. Lekanne Deprez RH, Groen NA, van Biezen NA, Hagemeijer A, van Drunen E, Koper JW et al. A t(4;22) in a meningioma points to the localization of a putative tumor-suppressor gene. Am J Hum Genet 1991; 48: 783-790.
2. Lekanne Deprez RH, Riegman PH, Groen NA, Warringa UL, van Biezen NA, Molijn AC et al. Cloning and characterization of MN1, a gene from chromosome 22q11, which is disrupted by a balanced translocation in a meningioma 8. Oncogene 1995; 10: 1521-1528.
3. Buijs A, van Rompaey L, Molijn AC, Davis JN, Vertegaal AC, Potter MD et al. The MN1-TEL fusion protein, encoded by the translocation (12;22)(p13;q11) in myeloid leukemia, is a transcription factor with transforming activity 24. Mol Cell Biol 2000; 20: 9281-9293.
4. van Wely KH, Molijn AC, Buijs A, Meester-Smoor MA, Aamoudse AJ, Hellemons A et al. The MN1 oncoprotein synergizes with coactivators RAC3 and p300 in RAR-RXR-mediated transcription 5. Oncogene 2003; 22: 699-709.
5. Chen Z, Fisher RJ, Riggs CW, Rhim JS, Lautenberger JA. Inhibition of vascular endothelial growth factor-induced endothelial cell migation by ETS1 antisense oligonucleotides 10. Cancer Res 1997; 57: 2013-2019.
6. Leo C, Chen JD. The SRC family of nuclear receptor coactivators 1. Gene 2000; 245: 1-11.
7. Sutton AL, Zhang X, Ellison TI, Macdonald PN. The 1,25(OH)2D3-regulated transcription factor MN1 stimulates vitamin D receptormediated transcription and inhibits osteoblastic cell proliferation 9. Mol Endocrinol 2005; 19: 2234-2244.
8. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation 2. Cell 1994; 77: 307-316.
9. Chakrabarti SR, Nucifora G. The leukemia-associated gene TEL encodes a transcription repressor which associates with SMRT and mSin3A 3. Biochem Biophys Res Commun 1999; 264: 871-877.
10. Fenrick R, Amann JM, Lutterbach B, Wang L, Westendorf JJ, Downing JR et al. Both TEL and AML-1 contribute repression domains to the t(12;21) fusion protein 10. Mol. Cell Biol 1999; 19: 6566-6574.
11. Lopez RG, Carron C, Oury C, Gardellin P, Bernard O, Ghysdael J. TEL is a sequence-specific transcriptional repressor 42. J Biol Chem 1999; 274: 30132-30138.
12. Carella C, Potter M, Bonten J, Rehg JE, Neale G, Grosveld GC. The ETS factor TEL2 is a hematopoietic oncoprotein 3. Blood 2006; 107 1124-1132.
13. Kawagoe H, Grosveld GC. Conditional MN1-TEL knock-in mice develop acute myeloid leukemia in conjunction with overexpression of HOXA9 13. Blood 2005; 106: 4269-4277.
14. Kawagoe H, Grosveld GC. MN1-TEL myeloid oncoprotein expressed in multipotent progenitors perturbs both myeloid and lymphoid growth and causes T-lymphoic tumors in mice 13. Blood 2005; 106: 4278-4286.
15. Ross ME, Mahfouz R, Onciu M, Liu HC, Zhou X, Song G et al. Gene expression proding of pediatric acute myelogenous leukemia 12. Blood 2004; 104: 3679-3687.
16. Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, Barjesteh van Waalwijk van Doom-Khosrovani S, Boer JM et al. Prognostically useful gene-expression profiles in acute myeloid leukemia 16. N Engl J Med 2004; 350: 1617-1628.
17. Heuser M, Beutel G, Krauter J, Dohner K, von Neuhoff N, Schlegelberger B et al. High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. Blood 2006; 108: 3898-3905.
18. Liu PP, Hajra A, Wijmenga C, Collins FS. Molecular pathogenesis of the chromosome 16 inversion in the M4Eo subtype of acute myeloid leukemia 9. Blood 1995; 85: 2289-2302.
19. Otto F, Lubbert M, Stock M. Upstream and downstream targets of RUNX proteins 1. J Cell Biochem 2003; 89: 9-18.
20. Castilla LH, Wijmenga C, Wang Q, Stacy T, Speck NA, Eckhaus M et al. Failure of embryonic hematopoiesis and lethal hemorrhages in mouse embryos heterozygous for a knocked-in leukemia gene CBFB-MYH11 4. Cell 1996; 87: 687-696.
21. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 1996; 84 321-330.
22. Sasaki K, Yagi H, Bronson RT, Tominaga K, Matsunashi T, Deguchi K et al. Absence of fetal liver hematopoiesis in mice deficient in transcriptional coactivator core binding factor beta 22. Proc Natl Acad Sci USA 1996; 93: 12359-12363.
23. Wang Q, Stacy T, Binder M, Marin-Padilla M, Sharpe AH, Speck NA. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis 8. Proc Natl Acad Sci USA 1996; 93: 3444-3449.
24. Castilla LH, Garrett L, Adya N, Orlic D, Dutra A, Anderson S et al. The fusion gene Cbfb-MYH11 blocks myeloid differentiation and predisposes mice to acute myelomonocytic leukaemia 2. Nat Genet 1999; 23: 144-146.
25. Higuchi M. O'Brien D, Kumaravelu P, Lenny N, Yeoh EJ, Downing JR. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia 1. Cancer Cell 2002; 1: 63-74.
26. Look AT. Oncogenic transcription factors in the human acute leukemias 5340. Science 1997; 278: 1059-1064.
27. Castilla LH, Perrat P, Martinez NJ, Landrette SF, Keys R, Oikemus S et al. Identification of genes that synergize with Cbfb-MYH11 in the pathogenesis of acute myeloid leukemia 14. Proc Natl Acad Sci USA 2004; 101: 4924-4929.
28. Landrette SF, Kuo YH, Hensen K. Barjesteh van Waalwijk van Doorn-Khosrovani S, Perrat PN, Van de Ven WJ et al. Plag1 and Plagl2 are oncogenes that induce acute myeloid leukemia in cooperation with Cbfb-MYH11 7. Blood 2005; 105: 2900-2907.
29. Cardone M. Kandilci A, Carella C, Nilsson JA, Brennan JA, Sirma S et al. The novel ETS factor TEL2 cooperates with Myc in B lymphomagenesis 6. Mol Cell Biol 2005; 25: 2395-2405.
30. Akashi K. Traver D, Miyamoto T, Weissman IL. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages 6774. Nature 2000; 404: 193-197.
31. Stanley KK, Szewczuk E. Multiplexed tandem PCR: Gene profiling from small amounts of RNA using SYBR Green detection 20. Nucleic Acids Res 2005; 33: E180.
32. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO) 3. Br J Haematol 1991; 78: 325-329.
33. Wijmenga C, Gregory PE, Hajra A, Schrock E, Ried T, Eils R et al. Core binding factor beta-smooth muscle myosin heavy chain chimeric protein involved in acute myeloid leukemia forms unusual nuclear rod-like structures in transformed NIH 3T3 cells. Proc Natl Acad Sci USA 1996; 93: 1630-1635.
34. Yanagisawa K, Horiuchi T, Fujita S. Establishment and characterization of a new human leukemia cell line derived from M4EO 2. Blood 1991; 78: 451-457.
35. Ayton PM, Cleary ML. Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9 18. Genes Dev 2003; 17: 2298-2307.
36. He LZ, Bhaumik M, Tribioli C, Rego EM, Ivins S, Zelent A et al. Two critical hits for promyelocytic leukemia 5. Mol Cell 2000; 6: 1131-1141.
37. Largaespada DA. Genetic heterogeneity in acute myeloid leukemia: maximizing information flow from MuLV mutagenesis studies 7. Leukemia 2000; 14: 1174-1184.
38. Barjesteh van Waalwijk van Doom-Khosrovani S, Spensberger D, de Knegt Y, Tang M, Lowenberg B, Delwel R. Somatic heterozygous mutations in ETV6 (TEL) and frequent absence of ETV6 protein in acute myeloid leukemia 25. Oncogene 2005; 24: 4129-4137.
39. Du Y, Jenkins NA, Copeland NG. Insertional mutagenesis identifies genes that promote the immortalization of primary bone marrow progenitor cells. Blood 2005; 106: 3932-3939.
40. Meester-Smoor MA, Vermeij M, van Helmond MJ, Molijn AC, van Wely KH, Hekman AC et al. Targeted disruption of the Mn1 oncogene results in severe defects in development of membranous bones of the cranial skeleton 10. Mol Cell Biol 2005; 25: 4229-4236.
41. Blobel GA. CREB-binding protein and p300: Molecular integrators of hematopoietic transcription. Blood 2000; 95: 745-755.
42. Chen CR, Kang Y, Massague J. Defective repression of c-myc in breast cancer cells: A loss at the core of the transforming growth factor beta growth arrest program 3. Proc Natl Acad Sci USA 2001; 98: 992-999.
43. Kang Y, Chen CR, Massague J. A self-enabling TGFbeta response coupled to stress signaling: Smad engages stress response factor ATF3 for Id1 repression in epithelial cells 4. Mol Cell 2003; 11: 915-926.
44. Kuo YH, Landrette SF, Heilman SA, Perrat PN, Garrett L, Liu PP et al. Cbf beta-SMMHC induces distinct abnormal myeloid progenitors able to develop acute myeloid leukemia 1. Cancer Cell 2006; 9: 57-68.
45. Grisendi S, Pandolfi PP. NPM mutations in acute myelogenous leukemia 3. N Engl J Med 2005; 352: 291-292.
46. den Besten W, Kuo ML, Williams RT, Sherr CJ. Myeloid leukemia-associated nucleophosmin mutants Perturb p53-dependent and independent activities of the Arf tumor suppressor protein 11. Cell Cycle 2005; 4: 1593-1598.